Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Gastroparesis and Functional Dyspepsia
NCT03941288Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in gastroparesis and functional dyspepsia (FD), sponsored by Mayo Clinic. Primary endpoint: Gastric Emptying Half-time (T1/2) of Solids at 4 weeks. Started Sep 2019; status: completed.
02
Drugs
cannabidiol
03
Conditions
gastroparesisfunctional dyspepsia (FD)
Beyond the preview
Go deeper on NCT03941288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941288.